What is Concord Drugs Ltd (538965) share price return in the past 10 years?

Concord Drugs Ltd share price has appreciated 4.3% annually (CAGR) over the past ten years.

What is the share price of Concord Drugs Ltd (538965)?

Company share prices are keep on changing according to the market conditions. The current trading price of Concord Drugs Ltd (538965) on 05-Jun-2026 09:07:00 at 09:07 is 82.98.

What is the P/E ratio of Concord Drugs?

The latest standalone P/E ratio of Concord Drugs as of 05-Jun-2026 is 102.16.

What is the P/B ratio of Concord Drugs Ltd (538965)?

The latest standalone P/B ratio of Concord Drugs Ltd (538965) as of 05-Jun-2026 is 2.18.

What is the 52-week high and low of Concord Drugs Ltd (538965)?

The 52-week high of Concord Drugs Ltd (538965) is Rs. 92.52 and the 52-week low is Rs. 29.00.

Concord Drugs Ltd (538965) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Concord Drugs Ltd (538965)
Brand: Concord Drugs

Concord Drugs Ltd (538965)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 538965 NSE: Pharmaceuticals & Drugs | Small Cap | Concord Drugs Share Price

Concord Drugs Ltd (538965)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 538965 NSE: Pharmaceuticals & Drugs | Small Cap | Concord Drugs Share Price

Key Metrics

Valuation Multiples

Market Cap

₹106 Cr.

Current Price

₹83

52-Week Low / High

₹29 / 93

TTM EPS

₹0.8

TTM Sales

₹75.9 Cr.

Book Value per Share

₹36.8

P/E Ratio

102.16

Higher than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

2.18

Higher than its 5-year historical median

Price to Sales (P/S)

1.40

Higher than its 5-year historical median

EV/EBITDA

27.39

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

0.87%

Underperforms industry median

Return on Capital Employed (ROCE)

4.73%

Underperforms industry median

Return on Assets (ROA)

0.51%

Operating Profit Margin

10.2%

Net Profit Margin

0.8%

Gross Profit Margin

5.6%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-14.63%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

2.17%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

-28.57%

Asset Quality

Promoter Holding

54.39%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹35 Cr.

Equity

₹13.2 Cr.

Face Value

₹10

All Time Low / High

₹11.68 / 92.52

Concord Drugs stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Weak

Check Price chart

Q.1 Is Concord Drugs Ltd a good quality company?

Concord Drugs Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Concord Drugs Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Concord Drugs Ltd vs industry peers?

Concord Drugs Ltd revenue CAGR is -6.38%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Concord Drugs Ltd?

Promoters hold 54.39% of the Concord Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Concord Drugs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 3.8% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	15.9%	8.8%	7.5%	6.2%	6.1%	15.7%	9.3%	6%	4.5%	4.7%	-
Value Creation Index ⓘ	0.1	-0.4	-0.5	-0.6	-0.6	0.1	-0.3	-0.6	-0.7	-0.7	-
Growth Parameters ⓘ
Sales ⓘ	50.7	57.5	51.8	48.1	51.3	51.4	59	51.3	43.3	36.9	76
Sales YoY Gr.	-	13.4%	-9.9%	-7.2%	6.8%	0%	14.8%	-13%	-15.7%	-14.6%	-
Adj EPS ⓘ	2.5	0.2	0.4	0.5	0.4	0.7	1.8	1	0.4	0.3	0.8
YoY Gr.	-	-91.1%	86.4%	26.8%	-26.9%	94.7%	146%	-47.3%	-56.3%	-28.6%	-
BVPS (₹) ⓘ	20.8	26.2	24.6	29.5	26.9	30.6	32.4	33.4	33.8	34.1	36.8
Adj Net Profit ⓘ	1.8	0.2	0.3	0.4	0.3	0.7	1.6	0.9	0.4	0.3	1
Cash Flow from Ops. ⓘ	3.6	1.7	6.9	1.2	2.5	1.6	0.8	2.2	2	3.2	-
Debt/CF from Ops. ⓘ	5.5	9.1	2	8.2	3.9	8	21.2	7	7.6	5.4	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-3.5%	-6.4%	-14.4%	-14.6%
Adj EPS ⓘ	-20.9%	-4.6%	-45.2%	-28.6%
BVPSⓘ	5.7%	4.9%	1.7%	0.9%
Share Price	4.3%	17.9%	44.5%	154%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	12.6	0.9	1.7	1.9	1.4	2.6	5.8	3	1.3	0.9	2.2
Op. Profit Mgn % ⓘ	16.4	9.6	8.8	7.6	6.5	6.3	9.5	8.5	8.5	10.2	5.6
Net Profit Mgn % ⓘ	3.5	0.3	0.6	0.9	0.6	1.3	2.7	1.7	1	0.8	1.4
Debt to Equity ⓘ	1.3	0.8	0.7	0.4	0.4	0.5	0.6	0.5	0.4	0.5	0
Working Cap Days ⓘ	263	251	474	620	416	293	241	296	348	414	118
Cash Conv. Cycle ⓘ	128	102	129	146	199	217	189	217	242	283	54

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	51	57	52	48	51	51	59	51	43	37
Operating Expenses ⓘ +	42	52	47	44	48	48	53	47	40	33
Manufacturing Costs	16	10	11	10	17	16	16	13	7	7
Material Costs	24	37	34	31	27	27	27	29	27	21
Employee Cost	2	3	2	2	3	3	4	4	4	3
Other Costs ⓘ	1	2	1	1	1	1	7	2	2	2
Operating Profit ⓘ	8	6	5	4	3	3	6	4	4	4
Operating Profit Margin (%)	16.3%	9.6%	8.8%	7.6%	6.5%	6.3%	9.5%	8.5%	8.5%	10.2%
Other Income ⓘ +	0	0	0	0	0	0	0	0	0	0
Exceptional Items ⓘ	0	0	0	0	0	4	0	0	0	0
Interest ⓘ	3	2	2	2	2	1	2	2	2	2
Depreciation ⓘ	3	3	2	2	1	1	2	2	2	1
Profit Before Tax ⓘ	3	1	1	0	0	4	2	1	1	1
Tax ⓘ	1	0	0	0	0	1	1	0	0	0
Profit After Tax	2	0	0	0	0	3	2	1	0	0
PAT Margin (%)	3.5%	0.3%	0.6%	0.9%	0.6%	6.4%	2.7%	1.7%	1.0%	0.8%
Adjusted EPS (₹)	2.4	0.2	0.4	0.5	0.4	3.8	1.8	1.0	0.4	0.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Concord Drugs - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	15	19	19	23	23	27	28	31	34	34
Share Capital ⓘ	7	7	8	8	9	9	9	9	10	10
Reserves ⓘ	8	12	11	15	15	18	20	22	24	24
Debt +	20	15	12	10	10	13	16	15	14	15
Long Term Debt	12	6	3	1	1	4	2	1	0	1
Short Term Debt	8	9	9	9	9	9	14	14	14	14
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	10	16	66	43	9	3	7	5	3	3
Others Liabilities ⓘ	8	5	8	7	16	7	5	6	5	6
Total Liabilities ⓘ	52	56	106	83	58	50	56	57	56	59
Fixed Assets
Net Fixed Assets ⓘ +	15	14	14	12	11	13	13	12	11	12
Gross Block	27	29	31	31	31	35	36	37	37	39
Accumulated Depreciation	12	15	17	19	20	21	23	25	26	28
CWIP ⓘ	0	0	0	0	1	0	1	1	2	2
Investments ⓘ	0	0	0	0	0	0	0	1	2	2
Inventories	8	11	19	19	16	12	17	18	18	19
Trade Receivables	25	16	71	48	25	21	23	16	14	13
Cash Equivalents	0	0	0	0	0	0	0	0	0	0
Others Assets ⓘ	4	15	3	3	5	4	2	8	9	11
Total Assets ⓘ	52	56	106	83	58	50	56	57	56	59

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	4	2	7	1	2	2	1	2	2	3
PBT ⓘ	3	1	1	0	0	4	2	1	1	1
Adjustment ⓘ	5	3	4	3	3	3	3	3	3	3
Changes in Working Capital ⓘ	-4	-1	2	-2	-1	-5	-4	-2	-2	-0
Tax Paid ⓘ	-1	-0	-0	-0	-0	-0	-1	-0	-0	-0
Cash Flow From Investing Activity ⓘ +	0	-1	-2	-0	-1	-4	-2	-2	-1	-2
Capex	0	-1	-2	-0	-1	-4	-2	-1	-1	-2
Net Investments	0	0	0	0	0	0	0	-1	0	0
Others ⓘ	0	0	0	0	0	-0	0	0	-0	0
Cash Flow From Financing Activity ⓘ +	-4	-4	-5	-1	-2	2	2	0	-1	-1
Net Proceeds from Shares ⓘ	0	0	3	0	1	0	0	2	1	0
Net Proceeds from Borrowing ⓘ	-0	0	0	-3	0	-0	-1	-1	-1	1
Interest Paid ⓘ	-3	-2	-2	-1	-1	-1	-1	-2	-2	-2
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-1	-2	-6	3	-1	4	4	0	1	-0
Net Cash Flow ⓘ	-0	-3	-0	0	-0	0	0	0	0	-0

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	12.32	0.94	1.69	1.92	1.41	13.06	5.77	3	1.29	0.87
ROCE (%)	15.9	8.84	7.49	6.17	6.06	15.69	9.3	5.97	4.47	4.73
Asset Turnover Ratio	0.95	1.06	0.64	0.51	0.73	0.95	1.11	0.91	0.77	0.64
PAT to CFO Conversion(x)	2	N/A	N/A	N/A	N/A	0.67	0.5	2	N/A	N/A
Working Capital Days
Receivable Days	190.40	130.60	305.90	454	262.60	164.10	134.90	139.50	127.90	131.70
Inventory Days	49.60	60.90	104.50	141.40	124.70	100.60	90.90	124.50	151.90	185.90
Payable Days	211.50	128.30	443.90	644.10	353.90	81.10	69.70	77.60	56.40	56.20

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Concord Drugs Ltd FAQs

The current trading price of Concord Drugs on 05-Jun-2026 09:07 is ₹82.98.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Concord Drugs stood at ₹105.9 Cr

The latest P/E ratio of Concord Drugs as of 04-Jun-2026 is 102.2.

The latest P/B ratio of Concord Drugs as of 04-Jun-2026 is 2.18.

The 52-week high of Concord Drugs is ₹92.52 and the 52-week low is ₹29.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Concord Drugs is ₹75.85 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Concord Drugs Ltd is a average quality company.

The key valuation ratios of Concord Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Concord Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Concord Drugs Ltd

No data to display

Concord Drugs Ltd (538965)

Concord Drugs Ltd (538965)

Concord Drugs stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Concord Drugs - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Concord Drugs Ltd FAQs

About Concord Drugs Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Concord Drugs Ltd (538965)

Concord Drugs Ltd (538965)

Concord Drugs stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Concord Drugs - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Concord Drugs Ltd FAQs

What is the share price of Concord Drugs?

What is the market cap of Concord Drugs?

What is the P/E ratio of Concord Drugs?

What is the P/B ratio of Concord Drugs?

What is the 52-week high and low of Concord Drugs?

What is the TTM revenue of Concord Drugs?

Is Concord Drugs Ltd a good quality company?

Is Concord Drugs Ltd undervalued or overvalued?

Is Concord Drugs Ltd a good buy now?

About Concord Drugs Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.